Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives by Weenink, B. et al.
cancers
Perspective
Immunotherapy in Glioblastoma: Current
Shortcomings and Future Perspectives
Bas Weenink 1, Pim J. French 1 , Peter A.E. Sillevis Smitt 1, Reno Debets 2,† and
Marjolein Geurts 1,*,†
1 Department of Neurology, Erasmus MC Cancer Institute, Be430A, PO Box 2040, 3000 CA Rotterdam,
The Netherlands; b.weenink@erasmusmc.nl (B.W.); p.french@erasmusmc.nl (P.J.F.);
p.sillevissmitt@erasmusmc.nl (P.A.E.S.S.)
2 Laboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute,
3000 CA Rotterdam, The Netherlands; j.debets@erasmusmc.nl
* Correspondence: m.geurts@erasmusmc.nl; Tel.: +31-10-704-4333
† Joint senior authors.
Received: 28 February 2020; Accepted: 19 March 2020; Published: 22 March 2020


Abstract: Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care
treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed
patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit
gained with immunotherapy in several extracranial tumor types spurred a variety of experimental
intervention studies in glioblastoma patients. These ranged from immune checkpoint inhibition to
vaccinations and adoptive T cell therapies. Unfortunately, almost all clinical outcomes were universally
disappointing. In this perspective, we provide an overview of immune interventions performed
to date in glioblastoma patients and re-evaluate their performance. We argue that shortcomings of
current immune therapies in glioblastoma are related to three major determinants of resistance, namely:
low immunogenicity; immune privilege of the central nervous system; and immunosuppressive
micro-environment. In this perspective, we propose strategies that are guided by exact shortcomings
to sensitize glioblastoma prior to treatment with therapies that enhance numbers and/or activation
state of CD8 T cells.
Keywords: adoptive T cell therapy; antigens; checkpoint inhibitors; clinical studies; glioblastoma;
immune privilege; tumor micro-environment; vaccines
1. Introduction
Glioblastomas are the most common type of primary brain cancer affecting 17/500,000 individuals
per year. The disease is clinically devastating with patients having a median survival of less than
15 months (hereafter referred to as mo) [1] despite standard-of-care (SOC), which currently consists
of surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ)
chemotherapy. Cancer immunotherapy, whereby one employs and/or activates the host’s own
lymphocytes to recognize and destruct cancer, has shown impressive results in the treatment of various
extracranial (metastatic) tumor types, e.g., melanoma, non-small cell lung cancer, and non-Hodgkin
lymphoma [2,3]. Three major immunotherapeutic approaches comprise immune checkpoint inhibition,
vaccination, and adoptive transfer of effector lymphocytes, which will be separately introduced in
the sections below. Outcomes of these immunotherapies to treat glioblastoma patients have been
rather disappointing and warrant a careful re-evaluation of clinical data in order to justify whether and
how to proceed with immune therapies to treat glioblastoma. In this perspective, we will summarize
the results from trials of the above-mentioned three types of immunotherapies conducted to date in
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glioblastoma, followed by a discussion on how current failure of monotherapies in glioblastoma relates
to three main determinants of resistance. Improved understanding of key glioblastoma:immune cell
interactions will guide the development and testing of novel approaches to sensitize glioblastoma to
immune therapies, and we will propose some of these combination treatments that may prove more
effective in the future.
2. Single Immune Therapies are not Effective in Glioblastoma
2.1. Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) block inhibitory receptors and their ligands often expressed by
immune cells, such as intratumoral T cells and myeloid cells, and tumor cells with monoclonal antibodies
to elicit an effective antitumor immune CD8 T cell response. Several so-called ‘immune checkpoints’
have been discovered over the last few decades, including the well-recognized molecules Programmed
cell death protein 1 (PD-1), Programmed death-ligand 1 (PD-L1) and Cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4). Therapies with these ICIs have shown impressive increases in survival and response
rates when compared to chemotherapy in a number of different cancer types [2,4–6]. ICIs that have been
subsequently approved by the Food and Drug Administration (FDA) and European Medicines Agency
(EMA) for the treatment of melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC),
Hodgkin lymphoma, head and neck squamous cell carcinoma (HNSCC), and urothelial carcinoma
include nivolumab and pembrolizumab targeting PD-1, and atezolizumab (for urothelial cancer and
NSCLC), avelumab (merkel cell carcinoma and RCC), and durvalumab (NSCLC) targeting PD-L1,
as well as ipilimumab targeting CTLA-4 (for melanoma and RCC) [2]. Table 1 lists the results from all
phase II and III trials that examined the clinical effect of ICIs in glioblastoma patients.
Table 1. Phase II/III clinical trials with immune checkpoint inhibitors in glioblastoma.




III PD-1 Nivolumab Bevacizumab R GB Each arm:~185 OS No impact
CheckMate 498




~275 OS No impact
CheckMate 548













None P GBR GB
P: 3
R: 27 (OS) 7.3 mo




(OS) 8.8 mo vs.10.3 mo














(OS) 13.7 mo vs.7.5 mo
NCT03291314 II PD-L1 Avelumab, axitinib None R GB 32 PFS6 18%
SEJ
NCT03047473 II PD-L1 SOC, avelumab None P GB 24 (PFS) 11.9 mo
NCT02336165 II PD-L1 SOC, durvalumab Historical P GBMGMT-unmeth. 40 OS12 60% vs. 50%
Abbreviations: MO, month; #, number of; RT, radiotherapy; SOC, standard of care; SS, second surgical procedure;
P, primary; R, recurrent; GB, glioblastoma; MGMT, O6-methylguanine-DNA methyltransferase gene; (un)meth.,
(un)methylated gene promoter; PFS6, 6-mo progression-free survival (PFS); OS12, 12-mo OS. Reference numbers
(NCT, PMID, PMCID) corresponding to each clinical trial are indicated in the ‘Clinical trial’ column. The ‘Endpoint’
column indicates which primary survival endpoint was assessed in each clinical trial. If a study only used a
secondary survival endpoint, the outcome measure was placed between parentheses.
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2.1.1. PD-1 Inhibitor Trials
CheckMate 143 (NCT02017717) was the first phase III trial to evaluate the efficacy of nivolumab +/−
ipilimumab versus Vascular Endothelial Growth Factor (VEGF)-inhibitor bevacizumab in patients with
recurrent glioblastoma [7]. The primary endpoint of this trial, overall survival (OS), was not improved
after treatment with nivolumab (n = 184) compared to bevacizumab (n = 185), with a median survival
time of 9.8 and 10.0 mo, respectively. Although responses were more durable in the nivolumab treatment
arm, no data was reported on long-term survivors amongst the entire patient cohort. Another phase III
trial, CheckMate 498, which assessed the clinical effect of nivolumab plus radiotherapy versus SOC in
patients with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated
glioblastoma (n = ~275 per arm) also failed to show impact on OS (NCT02617589) [8]. The counterpart of
this trial, CheckMate 548 (NCT02667587), in which similar treatments were tested in MGMT-methylated
glioblastoma patients (a phase II trial with n = ~160 per arm), showed no increase in progression-free
survival (PFS). It should be noted, however, that results from CheckMate 548 are still preliminary,
and OS data still has to mature before conclusions can be drawn.
A single-arm, phase II trial (NCT02550249) demonstrated the safety of presurgical and postsurgical
nivolumab in a set of primary (n = 3) and recurrent (n = 27) glioblastoma patients. Although no obvious
clinical benefit was observed after salvage surgery, two of the primary cases treated with nivolumab
showed long-term survival [9]. Patients treated with presurgical and adjuvant pembrolizumab resulted
in significant improvement of OS when compared to adjuvant administration alone (median 13.7 mo
vs. 7.5 mo) in a different randomized phase II trial for recurrent glioblastoma patients (n = 16 vs.
19) [10]. Neoadjuvant immunotherapy may increase the likelihood of targeting tumor-specific T cells
as the tumor bulk may be leveraged as a richer source for such T cells [10].
On an anecdotal level, two cases of glioblastomas with a high mutational burden (hypermutated
gliomas) resulting from a germline mismatch repair gene mutation have demonstrated dramatic
responses to anti-PD-1 therapy [11,12]. However, no tumor responses were observed in four other
patients with hypermutated recurrent glioblastomas treated with ICIs [13]. TMZ treatment can also
result in tumors with a high mutational load due to acquired mutations in the DNA repair genes
MSH2, MSH6, PMS2, and MLH2 [14–17], and these tumors are likely more immunogenic compared
to other glioblastomas. Hypermutation at glioblastoma diagnosis or at recurrence is associated with
enhanced numbers of CD8 T cells [18].
2.1.2. PD-L1 Inhibitor Trials
Besides PD-1, preliminary results are available from the first two single-arm phase II studies
which tested PD-L1 inhibitors in glioblastoma patients using efficacy as primary endpoints. In the first
study conducted in recurrent glioblastoma, the combination of anti-PD-L1 antibody avelumab and
axitinib (a tyrosine kinase inhibitor selective for VEGF receptors) did not meet the study threshold for
activity (six-mo PFS being 18%) [19]. In the second study, the addition of PD-L1 inhibitor durvalumab
to SOC resulted in a modest increase of OS for patients with newly diagnosed MGMT-unmethylated
glioblastoma (durvalumab 15.1 mo vs. historical controls 12.7 mo) [20].
2.2. Vaccination with Peptides or Dendritic Cells
Tumor vaccines induce a cellular and/or humoral immune response directed against one or
multiple tumor antigens. Vaccines generally constitute of peptides (single or combinations) or
protein(s) but may also consist of dendritic cells (DCs) either loaded with whole cell tumor lysates
or gene-engineered to express a certain (combination of) antigen(s). Immunostimulatory adjuvants
(e.g., poly ICLC) are usually co-administered with tumor vaccines to promote adaptive anti-tumor
immunity. Completed phase II and III trials using peptide and DC vaccines to target glioblastoma are
listed in Tables 2 and 3.
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Table 2. Phase II/III clinical trials with peptide vaccines in glioblastoma.


















III EGFRvIII SOC, PEP SOC, KLH P GBEGFRvIII+ 371 OS No impact
ACT-III
25586468 II EGFRvIII SOC, PEP Historical
P GB
EGFRvIII+ 65 PFS5.5 66% vs. 45%
ACT-II




















III Multiple TAA PEP Placebo R GBHLA-A24+
Treatment: 58
Control: 30 OS No impact
SL-701








I/II Multiple TAA SOC, PEP None P GBHLA-A2+ 16 (OS) 19 mo
SurVaxM~





Abbreviations: TAA, tumor-associated antigen; PEP, peptide vaccination; KLH, Keyhole limpet hemocyanin;
SS, second surgical procedure; P, primary; R, recurrent; GB, glioblastoma; HLA, human leukocyte antigen; #, number
of; PFS5.5, 5.5-mo PFS; OS6, 6-mo OS; PFS6, 6-mo PFS; OS12, 12-mo OS. The ‘Endpoint’ column indicates which
primary survival endpoint was assessed in each clinical trial. If a study only used a secondary survival endpoint,
the outcome measure was placed between parentheses.
2.2.1. Peptide Vaccination Trials
In gliomas, the variant III of the epidermal growth factor receptor (EGFRvIII), which results
from an in-frame intragenic deletion of EGFR exons 2–7, is present in approximately 20% to 30% of
glioblastomas and a recognized target in many peptide vaccination studies [21–23]. A peptide vaccine
targeting EGFRvIII (rindopepimut) displayed evidence for immunogenicity and efficacy in early phase
trials for EGFRvIII+ glioblastoma patients [24–27]. However, the randomized ACT IV study failed
to confirm this initial result and was terminated after interim analysis (mean OS for rindopepimut
20.1 mo versus control 20.0 mo) [28]. The lack of therapeutic effect in ACT IV may be explained by
the non-use of historical controls as a comparator (as has been done for the earlier ACT trials) and
the observation that EGFRvIII is not homogeneously expressed in all tumor cells, leading to immune
escape and recurrence of EGFRvIII-negative tumor cells Additionally, EGFRvIII expression is lost in
30–50% of glioblastoma samples upon tumor recurrence [16,24,29,30]. While rindopepimut and other
peptide vaccines for glioblastoma have elicited immune responses, their use has currently not resulted
in substantial clinical benefit.
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II Tumor lysate SOC, DC SOC P GB 34 PFS12 No impact
NCT03879512




None R GB pediatricR GB adult
Pediatric: 6




II Tumor lysate SOC, DC None P GB 31 PFS 12.7 mo
NCT00576537










21499132 II Tumor lysate SOC, DC None P GB 10 (OS) 28 mo
DENDR2
NCT02820584 I/II Tumor lysate
(1) SS, TMZ, DC










I/II Tumor stemcell mRNA SOC, DC None P GB 7 (OS) 25 mo
Abbreviations: GSC, glioma stem cell; TAA, tumor-associated antigen; P, primary; R, recurrent; GB, glioblastoma;
#, number of; SS, second surgical procedure; RT, radiotherapy; CT, chemotherapy; TTX, tetanus toxoid; OS6, 6-mo OS;
PFS12, 12-mo PFS. The ‘Endpoint’ column indicates which primary survival endpoint was assessed in each clinical
trial. If a study only used a secondary survival endpoint, the outcome measure was placed between parentheses.
2.2.2. DC Vaccination Trials
So far, one large phase III study has investigated the therapeutic potential of DC vaccination
in glioblastoma [31]. After tumor resection and chemoradiotherapy, 331 primary patients were
randomized to receive either TMZ and an autologous tumor lysate-pulsed DC vaccine (DCVax-L) or
TMZ plus placebo. As all patients were allowed to receive DCVax-L after tumor recurrence, there was
a high crossover fraction (~90%) in this trial. The study’s primary endpoint, PFS, has not yet been
evaluated and will be the subject of later analyses. The secondary endpoint, OS, has currently been
analyzed for the total intention-to-treat patient population and showed a 8-mo survival benefit for the
addition of DCVax-L to SOC. Mutation status of isocitrate dehydrogenase (IDH) 1 and 2 genes was
not determined for this trial, which may affect clinical outcome (as IDH mutant glioblastoma patients
have a better prognosis). Further maturation of the trial data is required to better assess the efficacy of
DCVax-L in newly diagnosed glioblastoma.
2.3. Adoptive Transfer of Effector Lymphocytes
Another intervention to provide a tumor-specific immune response is adoptive T cell therapy (AT).
In this setup, autologous T cells are expanded in vitro and returned to the patient in large numbers.
Early approaches made use of therapeutic T cells that are non-engineered, such as tumor-infiltrating
lymphocytes (TILs), while more recently recognized types of AT utilizes engineered (i.e., genetically
modified) T cells or other lymphocytes that express either chimeric antigen receptors (CARs) or
tumor-specific T cell receptors (TCRs). Tables 4 and 5 list the performed phase I and II trials with
adoptively transferred lymphocytes in glioblastoma.
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Table 4. Phase I clinical trials with gene-engineered T cells in glioblastoma.
































EGFRvIII+ 18 0/18 (0) 0/18 (0)
Abbreviations: SS, second surgical procedure; IL-2, interleukin 2; R, recurrent; GB, glioblastoma; OR, objective
response; CR, complete response; both according to Response Assessment in Neuro-Oncology (RANO) criteria.
Number of patients with responses = before dash. Total number of patients treated = after dash. Percentage of
responses = between brackets (bold).
Table 5. Phase I/II clinical trials with non-gene engineered T cells and other lymphocytes in glioblastoma.
Clinical Trial Phase Lymphocytes Other Treatment Indication # Patients OR (%) CR (%) OS













and NK cells None R GB 10 3/10 (30) 0/10 (0) -











R A or O
grade II-IV 19 8/19 (42) 1/19 (5) -










R A grade III 19 4/19 (21) 2/19 (11) -
Abbreviations: SS, second surgical procedure; IL-2, interleukin 2; CT, chemotherapy; CTL, cytotoxic T lymphocyte;
P, primary; R, recurrent; GB, glioblastoma; A, astrocytoma; O, oligodendroglioma; NR, not reported; OR, objective
response; CR, complete response; both according to Response Assessment in Neuro-Oncology (RANO) criteria.
Number of patients with responses = before dash. Total number of patients treated = after dash. Percentage of
responses = between brackets (bold).
2.3.1. Gene-Engineered T cells
Only a limited number of small CAR T cell trials for recurrent glioblastoma patients have been
carried out so far, and these mainly focused on feasibility and safety of adoptively transferred T cells
(Table 4). Importantly, CAR T cells have been shown to migrate from patient peripheral blood to
regions of active glioblastoma. In a phase I trial by O’Rourke and colleagues, ten patients with
EGFRvIII+ recurrent glioblastoma received a single dose of autologous CAR T cells directed against
EGFRvIII [32]. CAR T cell trafficking to the tumor could be verified by histological analysis of
surgical specimens obtained after therapy. No objective responses were observed in any of the patients
in this trial, and neither in a pilot study testing anti-EGFRvIII CAR T cell treatment in recurrent
glioblastoma patients after lymphodepleting chemotherapy [33]. These first negative clinical results
with anti-EGFRvIII CAR T cells may be explained by the considerable intratumor, intertumor and
temporal heterogeneity of EGFRvIII’s expression in glioblastoma. Indeed, antigen loss was observed
in a subset of patients after treatment. Of note, intracranial administration of CAR T cells targeting
interleukin-13 receptor alpha 2 (IL-13Rα2) resulted in robust antitumor immunity and complete tumor
regression in one patient with recurrent multifocal glioblastoma, which sustained for 7.5 mo following
CAR T cell infusions [34]. Currently, no results from TCR T cell therapy trials have been reported for
glioblastoma patients. Two phase II studies (NCT03412877, NCT04102436) have recently been initiated
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by the National Cancer Institute (NCI) that will assess the clinical response after adoptive transfer of T
cells genetically engineered to express TCRs reactive against neoantigens in patients with glioblastoma
and other (metastatic) cancer types.
2.3.2. Non-Engineered T Cells and Other Lymphocytes
Other adoptive transfer approaches that have been tested in glioblastoma include those with
non-engineered lymphocytes, such as TILs, T cell clones derived from peripheral T cells, natural
killer (NK) cells and lymphokine-activated killer (LAK) cells (Table 5). The use of TILs, expanded
from fresh surgical specimens and locally re-administered together with IL-2, has been attempted
in a single small study for recurrent malignant glioma [35]. Although glioblastoma-infiltrating
lymphocytes can be successfully expanded in vitro [36], these protocols are generally not yet efficient
(e.g., when compared to melanoma) and TILs demonstrated poor function and severe exhaustion [37,38].
Multiple non-overlapping immunosuppressive mechanisms may drastically impair the yield of
glioblastoma-infiltrating lymphocytes (see below). During the last decades, early phase trials have
not yet demonstrated clear clinical value for both NK- and LAK-based adoptive transfer. A challenge
of NK and LAK therapy is the requirement of co-transfusion with immune stimulants, such as IL-2,
which may result in significant toxicities [39]. Other early phase trials have focused on autologous
cytomegalovirus (CMV)-specific T cells to target glioblastoma [40]. In these studies, CMV-specific
T cells were generated in vitro following stimulation of peripheral blood mononuclear cells (PBMC)
with peptides derived from CMV phosphoprotein (pp)65. So far, no objective tumor responses have
been observed, neither as a single treatment nor when combined with a pp65 mRNA-loaded DC
vaccine [41]. It is noteworthy that large comprehensive studies did not provide evidence for the
presence of CMV in glioblastomas, questioning its use as target [40,42]
In summary, results from a considerable number of clinical trials testing ICIs, vaccines, and
adoptive transfer have been reported for primary and recurrent glioblastoma patients. Unfortunately,
no phase III trials have currently shown significant improvement in OS. Although we should await
the results from other clinical trials, the so far limited results using PD-1 or PD-L1 inhibitors suggest
that alternative approaches should be tested. However, remarkable therapeutic responses have been
observed in some studies and the observation of long-term response of a minority of patients to
immune interventions demonstrates the potential of these approaches to target glioblastoma. The early
and promising results of neo-adjuvant PD-1 blockade warrants larger randomized clinical trials of
this regimen in glioblastoma patients. We also recommend testing ICIs in the setting of recurrent
TMZ-treated diffuse low-grade gliomas (LGGs), as hypermutation is correlated to the number of TMZ
cycles and occurs most often in tumors progressing from lower grade gliomas (up to 50%) [16,17]
The following section will give an up-to-date overview of important mechanisms that relate to
glioblastoma immunotherapy resistance.
3. Immune Therapy Resistance in Glioblastoma
Here, we describe the pathophysiology underlying the immune therapy resistance of glioblastoma
in relation to three key issues: low immunogenicity; immune privilege of the central nervous system
(CNS); and immune suppressive micro-environment.
3.1. Low-Immunogenicity of Glioblastoma
The mutational burden and consequently neoantigen burden in glioblastoma is generally low
compared to other immunogenic tumor types, such as melanoma and non-small cell lung cancer [43,44].
Different studies have predicted the presence of only a handful of low expressed glioma neoantigens
derived from mutated genes [44–47]. While other, non-mutated targets (e.g., Cancer Germline
Antigens (CGAs)) are frequently expressed in glioblastoma, expression levels are low or, at best,
highly variable [44,48]. Besides gene expression, tumor antigens need to pass through the antigen
processing and presenting machinery (APM) to enable recognition by T cells. Strikingly, a large-scale
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immunopeptidome study did not identify any human leukocyte antigen (HLA)-presented mutated
peptides nor peptides derived from frequently targeted CGAs in glioblastoma patient serum (n = 142)
or tumor tissue (n = 10) [49]. A different study showed that HLA class I and II molecules are not
detectable in ~50% or more of glioblastoma patient tissues (n = 47) and expression of tapasin, an APM
protein that mediates interaction between MHC class I molecules and the transporter associated with
antigen processing (TAP), was downregulated in a subset of patient specimens [50]. Other components
of the APM, such as TAP1/2 and β2-microglobulin, were still intact in these specimens. We advocate
in-depth studies into the APM and immunogenicity of glioblastoma since the presence of a single
immunogenic target antigen may potentially already suffice to start an antitumor immune response [51]
3.2. Immune Privilege of CNS
Under homeostatic conditions, leukocytes are not present in the brain parenchyma. There are,
however, small numbers of immune cells, including T cells, in the choroid plexus stroma and the
cerebrospinal fluid, as well as the subarachnoid and the perivascular spaces [52]. Microglia are the
most prominent immune cells in the brain and they serve as tissue-resident macrophages of the CNS.
In fact, microglia, together with macrophages and dendritic cells in the meninges and perivascular
spaces, form the first line of defense against pathogens [53]. Despite their absence in the brain
under homeostatic conditions, T cells are able to extravasate from blood vessels in the case of a
primary malignant brain tumor. The number of intratumoral CD8 T cells in glioblastoma remains,
however, small (0–12% of all cells) [54] when compared to extracranial tumor types [55]. In line
with other cancers, CD8 T cell numbers have been reported to be associated with favorable outcome
and survival in glioblastoma [56–58]. CD8+ T cell numbers, in combination with neoantigen quality,
can also predict a subgroup with longest survival [59]. The abundance and tumor invasiveness of CD8
T cells in glioblastoma is higher than in LGGs, which is accompanied by an increased expression of
chemo-attractants CXCL9, CXCL10 and intercellular adhesion molecule (ICAM)1 [44]. Nevertheless,
a substantial part of CD8 T cells display a PD-1+, LAG-3+, TIGIT+, CD39+, KLRG1−, and CD57− profile,
indicative of T cell exhaustion [37,60] and suggestive that factors in the glioblastoma micro-environment
negatively control an anti-tumor CD8 T-cell response.
3.3. Immune-Suppressive Micro-Environment
The glioblastoma micro-environment is hostile towards an effective anti-tumor immune response,
thereby negatively impacting the effect of immune therapies [61]. Here, we explicitly zoom in on the
major cell types and mediators reported to contribute to an immune-suppressive micro-environment
in glioblastoma. This sections aims to describe and discuss the role that these defined cells and
mediators in the glioblastoma micro-environment potentially play in suppressing immunotherapy for
glioblastoma. More comprehensive reviews that elaborate on other cell types and mediators present in
the glioblastoma micro-environment are published elsewhere [62,63].
3.3.1. Immune-Suppressive Cells
Tumor associated macrophages (TAMs) are highly prevalent in glioblastoma, and up to 50%
of the glioblastoma micro-environment consists of these cells [64]. The number and function of
TAMs are shaped by glioblastoma-derived soluble factors, such as the chemo-attractant CCL-2 and
colony-stimulation factor 1 (CSF-1) [65]. These cells have a pleiotropic capability to suppress CD8 T
cell activity in glioblastoma due to, at least in part, surface-expression of IL-4Rα and the production of
arginase and inducible nitric oxide synthase (iNOS). Activation of IL-4Rα up-regulates the expression
of transforming growth factor (TGF)-β (see below for immune-suppressive actions of TGF-β), whereas
arginase and iNOS deplete key amino acids from the extracellular environment, which in turn inhibits
T cell proliferation [66].
Regulatory T cells (Tregs) are a subset of CD4 T cells that generally express the transcription factor
Foxp3. The proportion of CD4 cells being Tregs is highly variable in glioblastoma (i.e., 4–55%) [67,68].
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Tregs are immune-suppressive as they secrete TGF-β and IL-10, which by limiting T cell interleukin-2
and interferon (IFN)-γ production, result in hampered function of CD8 T cells [37]. Glioblastomas
attract Tregs from the periphery via soluble factors, such as tumor cell-derived CCL-22 [69]. Once within
the tumor tissue, Tregs can become activated via TAMs that express T-cell immunoglobulin and mucin
domain–containing molecule 4 (TIM4). TIM4-expressing myeloid cells can phagocytose tumor-specific
T cells that express phosphatidylserine (PS; a possible measure of dying cells), which results in
the expression of the immune-suppressive aldehyde dehydrogenase and TGF-β, which in turn
stimulate the activity of Tregs [37]. In addition, indoleamine 2,3-dioxygenase (IDO; discussed further
below) produced by dendritic cells in tumor-draining lymph nodes, recruits and activates Tregs in
glioblastoma [69].
3.3.2. Immune-Suppressive Mediators
As already mentioned above, TGF-β is a pleiotropic cytokine that plays a central role in immune
suppression in the glioblastoma micro-environment [70]. TGF-β has three isoforms, and all are (over-)
expressed in glioblastoma [71]. TGF-β suppresses IL-2 dependent T cell survival, and further impairs
cytotoxic T cells’ activity via inhibiting the expression of immune-stimulatory and effector molecules,
such as IL-6, IL-10, IFN-γ, granzymes A and B, perforin, and Fas ligand [11]. Additionally, it drives
development of naive T cells into Tregs [72].
Glioblastomas take up and metabolize tryptophan. High IDO activity leads to the depletion of
tryptophan from the local micro-environment, and activation of the amino acid starvation-sensing
response pathway involving the broadly expressed general control non-derepressible kinase (GCN2).
This pathway is an important immune modulator as activation thereof in T cells leads to anergy and
subsequent cell death [73]. Alternative routes of tryptophan catabolism via tryptophan-2,3-dioxygenase
(TDO) may be of special interest in glioblastoma, as this gene is highly expressed in glioblastoma [73].
4. Strategies to Sensitize Glioblastoma to Immune Therapies
The disappointing results of clinical trials on immunotherapy in glioblastoma as discussed in
previous sections, reflect the shortcomings of the current immunotherapeutic treatment strategies.
Strategies to enhance the sensitivity of glioblastomas to immune therapies are clearly needed.
These strategies could address the low-immunogenicity of glioblastoma, attempt to increase the CD8
T cell influx and activity, and/or strive to downregulate the immunosuppressive micro-environment
(Figure 1).
4.1. Strategies to Enhance the Efficacy of ICI
The strategies that are currently investigated to enhance the efficacy of ICI in glioblastoma address
two key points: downregulating the immune suppressive micro-environment and increasing the CD8
T cell influx.
4.1.1. Downregulating the Immune Suppressive Micro-Environment
Many attempts have been undertaken to target TAMs in glioblastoma. These attempts have
particularly focused on CSF-1R inhibition as this receptor strongly mediates recruitment of TAMs into
tumor tissue [65]. Indeed, combination therapies of TAM-targeting and ICI were shown to increase
the number of CD8 T-cells in the tumor in pre-clinical models in melanoma, leading to an increased
rejection of tumors [74]. Pre-clinical data of this approach in glioblastoma are lacking, but two phase
I trials using this combination therapy are now ongoing: Cabiralizumab, an anti-CSF-1 receptor
monoclonal antibody, in combination with nivolumab, is tested in solid cancers, including glioblastoma
patients (NCT02526017). Additionally, BLZ945, a CSF-1 inhibitor, is tested as monotherapy and in
combination with spartalizumab, a novel anti-PD1 monoclonal antibody, in solid cancers, including
glioblastoma (NCT02829723).
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Figure 1. Exemplary immune-suppressive mechanisms in glioblastoma, and therapeutic interventions to
sensitize glioblastoma for T cell treatments. (A) Tumor-associated macrophages (TAMs) and regulatory
T cells (Tregs) release immunosuppressive mediators in the glioblastoma microenvironment, such as
TGF-β and IL-10 (the latter not depicted). Local production of indoleamine 2,3- dioxygenase (IDO)
or tryptophan-2,3-dioxygenase (TDO) by glioblastoma cells depletes tryptophan from the tumor
micro-environment, having an adverse effect on the functi of CD8 T c . Also, the immune
checkpoint, PD-L1, expressed on glioblastoma cells can engage with PD-1+ T cells to suppress their
effector function. (B) Monoclonal antibodies directed against glucocorticoid-induced TNFR related protein
(GITR) and IL-2 receptor α (IL-2Rα) may specifically deplete intratumoral Tregs. Immunosuppressive
effects exerted by TGF-β can be abolished by small molecule inhibitors, such as galunisertib. IDO and
TDO inhibitors (the latter not depicted) may restore tryptophan levels in the micro-environment, causing
re-activation of CD8 T cells. TAM-induced immunosuppression may be counteracted using inhibitors
against colony-stimulation factor 1 (CSF1) or its receptor. Oncolytic virotherapy and radiotherapy may
cause increased release of antige , which turn may result in e hanced numbers and activation of
intratumoral CD8 T cells. When (one or several of) these nterventions are combined with vaccines,
immune checkpoint inhibitors (ICIs) or adoptive transfer of effector lymphocytes, this may significantly
improve the recruitment and/or activation state of glioblastoma-specific CD8 T cells and lead to restoration
of the efficacy of these T cell treatments in glioblastoma.
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Early attempts to deplete Tregs in glioblastoma made use of the constitutive expression by these
cells of the high affinity IL-2 receptor α (IL-2Rα/CD25). In a phase I clinical trial in glioblastoma,
treatment with the anti-IL-2Rαmonoclonal antibody daclizumab in combination with EGFRvIII peptide
vaccination, significantly reduced the frequency of circulating Tregs [75]. This study result warrants a
follow-up study to investigate the beneficial effect of daclizumab treatment in glioblastoma. Another
potential Treg target is the costimulatory receptor glucocorticoid-induced TNFR related protein (GITR).
Indeed, intra-tumoral treatment with anti-GITR antibody leads to depletion of Tregs in a glioma murine
model [76]. In addition, treatment with anti-GITR plus anti-PD1 antibodies in a murine ovarian cancer
model led to dramatic increases in the numbers of CD4 and CD8 T cells with a concomitant decrease in
Tregs and myeloid-derived suppressor cells in these tumors [77]. In line with these preclinical results,
a phase II study testing the combination of a GITR antibody (INCAGN1876), an anti-PD1 antibody
and stereotactic radiosurgery for recurrent glioblastoma has just opened (NCT04225039).
The small molecule inhibitor galunisertib (LY2157299 monohydrate) targets the serine-threonine
kinase domain of TGF-βRI, abrogates the phosphorylation of SMAD2, the initial intracellular signaling
protein of the TGF-β pathway. In a phase II study (n = 158), no clinical benefit was found when
comparing galunisertib to lomustine chemotherapy and to galunisertib plus lomustine chemotherapy
in recurrent glioblastoma [78]. Moreover, of the 127 tumor specimens examined, no difference between
immune cells or immune mediators was found before and after treatment. However, in the patients
who were treated with galunisertib only, there was a trend towards an association between the number
of galunisertib cycles and the CD4 and lymphocyte cell counts [79]. These data should be interpreted
with caution due to the small patient number but do suggest that TGF-β blockade renders tumors
susceptible to immune therapies. At the moment of this writing, there are no ongoing studies with
TGF-β blockade in glioblastoma.
Monotherapies with IDO inhibitors are currently being explored in glioblastoma (NCT02052648);
no clinical trials in glioblastoma are ongoing with TDO-inhibitors. Interestingly, treatment with the
IDO-1 enzyme inhibitor BGB-5777, combined with anti-PD1 antibody, as well as radiotherapy in
a mouse model of glioblastoma, increased the absolute numbers of CD8 T cells in the tumor and
increased survival, when compared to monotherapy with either single agent [80]. The combination of
an IDO-1 inhibitor (epacodostat) and ICI is currently under investigation in a phase I trial assessing
solid cancers, including glioblastoma (NCT02327078).
4.1.2. Increasing the CD8 T Cell Influx
There is an increasing amount of evidence that oncolytic viruses can be used to sensitize
glioblastoma to immune therapies. In fact, it has even been speculated that the immune stimulatory
effect of oncolytic viruses is more relevant than their direct oncolytic effects. For example, in an
experimental glioma mouse model using oncolytic Newcastle disease virus (NDV), intratumoral
administration was associated with increased immunogenicity, elevated numbers of CD8 T cells and
reduced accumulation of TAMs in 50% of the treated mice [81]. A notable benefit of combining oncolytic
virotherapy and ICI came from preclinical studies in which one tested: measles virus and anti-PD-1
antibody; vesicular stomatitis virus (VSV) and anti-PD-1 antibody; and adenovirus Delta-24-RGDOX
(expressing the immune co-stimulatory OX40 ligand) and anti-PD-L1 antibody, as well as reovirus and
anti-PD-1 antibody, which all demonstrated therapeutic benefits against the GL261 glioma model [82].
In phase I trials where patients with recurrent glioblastoma were treated with intratumoral adenovirus
DNX-2401 [83] or PVSRIPO (a modified polio virus) [84], imaging showed an increase in tumor size
and atypical contrast enhancement after treatment in a subset of patients, which has been interpreted
as an inflammatory-mediated response. Indeed, histologic analysis of a resected lesion identified
inflammatory-mediated responses with high numbers of macrophages and CD8 T cells [83]. The three
(12%) responders in the DNX-2401 trial had 10- to 1000-fold increases in interleukin-12p70 in their
sera, which is recognized for its induction towards T helper 1 responses and cell-mediated immunity.
Currently, it is unclear whether the intra-tumoral CD8 T cells expressed immune checkpoints, which
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would advocate the additional use of ICI next to vaccinations. A phase 2 clinical trial with DNX-2401
plus pembrolizumab is currently recruiting patients with recurrent glioblastoma (NCT02798406).
As mentioned in previous sections, neoadjuvant ICI may sensitize glioblastoma to other immune
therapies. Indeed, molecular analyses revealed enhanced expression of chemo-attractants (i.e., CXCL10,
CCL4, and CCL3L1) and presence of T cells in the tumor when compared with a historical group of
glioblastoma samples. Interestingly, T cell receptor clonality analyses also showed more diversity in the
group treated with nivolumab with an association between TCR clonotype diversity and survival [9].
A gene signature related to IFN-γ responsiveness and a decrease in the number of tumors with cell
cycle gene expression signatures was noted in a separate neoadjuvant ICI study [10]. Both studies
suggest neoadjuvant treatment could be further harnessed therapeutically via combination with
other therapies.
Radiotherapy is another potential glioblastoma sensitizer to ICI, as it opens the blood-brain-barrier,
increases the amount of TILs and up-regulates expression of PD-L1 in mice with intracranial gliomas [85].
Additionally, tumor cell death induced by radiotherapy releases tumor-associated antigens into the
micro-environment, leading to increased antigen presentation [86]. Treatment with fractionated
(high dose) radiotherapy has been shown to up-regulate the expression of PD-L1 in in vitro glioblastoma
cell lines [87], and anti-PD1 treatment is effective particularly in combination with radiotherapy in
glioma models [85]. In patients, the efficacy and side effects of hypofractioned radiation therapy still
have to be determined. Combination therapies with (hypofractionated) radiation and ICI in primary
glioblastoma (NCT02313272, NCT02648633, NCT02829931, NCT02866747) are open and currently
recruiting patients.
Treatment with a COX-2 inhibitor, which blocks IL-6, IL-10 and GM-CSF in glioma mouse models,
ultimately leading to increased numbers of intra-tumoral T cells, may provide yet an additional
approach to sensitize glioblastoma to ICI [88].
Low-dose chemotherapy also increases the influx of CD8 T cells into the tumor in pre-clinical
models of glioblastoma [89], but the peripheral lymphodepletion in patients treated with chemotherapy
may counteract these beneficial effects [79]. Additionally, TMZ administration has been shown to have
a detrimental effect on the formation of a memory CD8+ T cell response against glioblastoma [90].
This makes (low dose) chemotherapy unlikely to be an attractive sensitizer for anti-glioblastoma T
cell treatment.
4.2. Strategies to Enhance the Efficacy of Vaccinations
Since tumor-restricted antigens are scarce, and many are not shared by a large number of patients,
personalized vaccine approaches may be of particular interest for the treatment of glioblastoma.
Recently, safety and feasibility results from two single arm, open label, phase I trials were reported that
both targeted patient-specific repertoires of neoantigens in newly diagnosed glioblastoma. In the first
study, the vaccine NeoVax targeted multiple mutated peptides that were selected based on predicted
HLA-binding and mRNA expression of the source antigen in tumor tissue (n = 8) [47]. The other
study (n = 15) conducted by the Glioma Actively Personalized Vaccine Consortium (GAPVAC) utilized
a similar approach but also included mass spectrometry analysis of patient tumor tissues to select
whether mutated peptides are indeed presented by HLA molecules and included unmutated peptides to
complete their vaccines [46]. The preliminary median OS data of the GAPVAC-101 trial are encouraging
(29.0 mo) and argue that larger and better controlled clinical trials need to be executed.
4.3. Strategies to Enhance the Efficacy of Adoptive Transfer of Effector Lymphocytes
Much of the potential of adoptive T cell therapy for glioblastoma lies in modification of the cells
themselves [91]. The new generation CAR T cells are armed with immune stimulatory cytokines
that improve CAR T cell expansion and persistence, while rendering them resistant to the immune
suppressive tumor micro-environment. In glioblastoma studies, CAR T cells targeting IL-13Rα2 were
modified to over-express transgenic IL-15 and demonstrated that IL-15 cytokine secretion was T cell
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activation dependent and resulted in improved CAR T cell persistence in vitro. This also translated
into significantly improved anti-tumor activity in vivo [92].
Gene editing to further enhance the efficacy of CAR-T cells is still in its very early days, especially
in glioblastoma. The knock-out of the intracellular signaling molecule diacylglycerol kinase (DGK)
using a CRISPR/Cas9-based strategy in EGFRvIII CAR T cells led to a significantly less sensitivity
to TGF-β mediated suppression and did not show significant loss of effector function following
repeated stimulation. These in vitro findings translated to in vivo studies in a mouse glioma model as
tumor-bearing mice receiving double knock-out EGFRvIII CAR T cells had significantly reduced tumor
burden with increased frequencies of tumor-infiltrating lymphocytes [93]. The-knock in of genes to
enhance CAR T cell function has not yet been tested in glioblastoma [91].
Multitarget engineered T-cells for glioblastoma to overcome inter- and intratumor cell antigen
heterogeneity are quickly entering the field. Trivalent CAR T cells targeting three glioblastoma
associated antigens (HER2, IL-13Rα2-, and EphA2-specific CAR molecules, all expressed simultaneously
on the T cell surface) are now designed [94]. Even more recently, other antigens have been targeted
including CSPG4 [95] or B7-H3 [96] and chlorotoxin [97] as has been eloquently demonstrated in
preclinical studies. These proof-of-concept studies are promising; however, the question remains if
these CAR T cell products will be efficient when tested clinically [91]. Due to the variation in antigen
expression in glioblastoma, target selection on a patient-by-patient basis may be necessary.
4.4. Combination of ICI, Vaccination, and Adoptive Transfer of Effector Lymphocytes
In a trial using neoantigen-targeting vaccines, two out of 8 vaccinated patients had vaccine-specific
T-cell responses [47]. In these patients, thorough immune monitoring revealed that vaccine-induced
T cells (predominantly CD4 T cells) were able to migrate to the tumor site in the brain. These T-cells
predominantly had an exhausted phenotype and expressed multiple immune checkpoints, suggesting
the option of these vaccines combining with ICI [47]. In a second peptide vaccination trial, using both
non-personalized and personalized vaccines, 12 out of 13 patients treated with the non-personalized
vaccine had CD8 T cells that recognized at least one of the vaccine protein, and 8 out of 10 patients treated
with the personalized vaccine had CD4 T-cells that recognized neoantigens. Clinical trials combining
a peptide vaccine plus a checkpoint inhibitor in glioblastoma are currently ongoing (NCT02529072,
NCT03014804).
The effector functions of CAR-T cells have previously been shown to be enhanced by ICI in glioma
models [98]. Currently, phase I studies combining anti-EGFRvIII CAR-T cells with pembrolizumab
(NCT03726515) and anti-IL-13Rα2 CAR-T cells with or without ipilimumab and nivolumab (NCT04003649)
are now recruiting patients with glioblastoma.
5. Outstanding Questions for Future Research
Rational combinatorial approaches will be required in order to achieve optimal efficacy of
immunotherapy in patients with glioblastoma. Many unanswered questions remain. First, most
patients with glioblastoma are treated with dexamethasone, and the immune suppressive effects of this
drug inevitably intervene with immunotherapy trials. For example, in a trial using neoantigen-targeting
vaccines [47], T-cell responses were induced only in the patients who did not receive dexamethasone
in the vaccine priming phase.
Second, the treatment of CNS pathology in general is limited by poor drug penetration of
the blood-brain-barrier, which is significantly prohibitive for compounds of sizes greater than
400–600 Da [99]. The calculated molecular mass of nivolumab, which is administered in the peripheral
blood, is 146 kDa. Although the blood-brain-barrier is disrupted in glioblastoma, it is unknown to
what extent systemically administered antibodies such as nivolumab reach the tumor site. Of interest,
patients with brain metastases of melanoma do respond to systemically administered nivolumab [100],
which suggests that the blood-brain-barrier is not per se limiting towards treatment effect. We argue
that pharmacokinetic assessments should be included in future studies. In fact, modern imaging
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technologies may facilitate the assessment of drug delivery, and radioisotopes coupled to, among
others, monoclonal antibodies may aid drug delivery [101].
Third, accurate predictive biomarkers to select patients that will benefit from the immunotherapeutic
treatment are obviously needed. Even in the absence of benefit for the total patient group, there may
very well be a subset of patients that does respond. For example, 8% of patients responded to nivolumab
in the CheckMate 143 trial of recurrent glioblastoma [7]. Along these lines, it is highly encouraging that
the design of clinical trials for glioblastoma is more and more taking into account the collection of tumors
before and after treatment [9,10,79].
6. Conclusions
Results of conducted randomized trials on immunotherapy in glioblastoma inevitably, and almost
collectively, point to a lack of efficacy. These disappointing results may reflect the shortcomings of the
current immunotherapeutic treatment strategies. Glioblastomas are very low-immunogenic tumors,
located in a T-cell poor CNS compartment, and embedded in a particularly immune suppressive
micro-environment. We, therefore, recommend future treatment strategies that sensitize glioblastoma
to immune therapies. Rationally designed combinatorial immunotherapeutic approaches offer
tremendous opportunities to ultimately fulfill the high promises of immunotherapy in glioblastoma.
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